Professor David Mutimer

Institute of Immunology and Immunotherapy
Professor of Clinical Hepatology
Honorary Consultant Hepatologist to the QE Hospital Liver and Hepatobiliary Unit

Contact details

Institute of Immunology and Immunotherapy
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

David Mutimer is Professor of Clinical Hepatology at the University of Birmingham and Honorary Consultant Hepatologist to the Queen Elizabeth Hospital Liver and Hepatobiliary Unit, Birmingham. He is an Area Lead (Clinical Trial Infrastructure) in the NIHR Birmingham Liver Biomedical Research Unit.


  • MBBS (Melbourne 1980)
  • MD (Melbourne 1998) 


David graduated from Monash University, Melbourne in 1980 and commenced specialist training in Internal Medicine and Gastroenterology in Melbourne. 

In 1986 he came to the UK and worked as research fellow at the University of Newcastle-upon-Tyne from 1986-89. From 1987-89 he held the British Digestive Foundation Amelia Waring Research Fellowship. 

In 1989 he moved to the Birmingham Queen Elizabeth Hospital Liver Unit, and has worked there since that time. In 1996 he was appointed Senior Lecturer in Hepatology (Birmingham University) and Honorary Consultant Hepatologist to the Liver and Hepatobiliary Unit. He was Clinical Service Lead for Hepatology at the Queen Elizabeth Hospital from 2000 to 2010.

In the field of hepatitis infection, he has focused on antiviral treatment, drug resistance, epidemiology and natural history of infection. In the field of liver transplantation, his principal interests have included the treatment and prevention of recurrent viral hepatitis and opportunistic infections.

He has established and leads the QE Hospital Viral Hepatitis clinical service. Since 2015, he has been the Clinical Director of the Birmingham NHSE Operational Delivery Network for Viral Hepatitis. He is the West Midlands representative on the NHSE Hepato-Pancreato-Biliary (HPB) Clinical Reference Group (CRG), and is also a member of the NHSE Viral Hepatitis CRG.

He is a fellow of the Royal College of Physicians of England and of the Australasian College of Physicians. 

He has published nearly 200 original and invited articles in peer-reviewed journals. He was associate editor of Gut (2007-9) and is or has been a member of the editorial boards of Gut, the Journal of Hepatology, Liver Transplantation, and Alimentary Pharmacology and Therapeutics.





Chief investigator and/or Principal Investigator in a number of studies, principally involving antiviral treatment. 

David is one of the PI’s for the NIHR Birmingham Liver Biomedical Research Unit, and leads the Research Forum of the Liver Clinical trials group.

Other activities


  • Clinical Service Lead for Liver Medicine, Birmingham QE Hospital Liver and Hepatobiliary Unit


Recent Publications

Paolo De Simone, Renato Romagnoli, Francesco Tandoi, Paola Carrai, Giorgio Ercolani, Eugenia Peri, Fausto Zamboni, Laura Mameli, Fabrizio Di Benedetto, Umberto Cillo, Luciano De Carlis, Andrea Lauterio, Luigi Lupo, Giuseppe Tisone, Martin Prieto, Carmelo Loinaz, Antoni Mas, Abid Suddle, David Mutimer, Bruno Roche, Andrea Wartenberg-Demand, Gabriele Niemann, Heike Böhm, Didier Samuel. Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study. Transplantation (in press).

Xavier Forns, Didier Samuel, David Mutimer, Stefano Fagiuoli, Miquel Navasa, Kosh Agarwal, Marina Berenguer, Massimo Colombo, Kerstin Herzer, Frederik Nevens, Bjorn Daems, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, Holly Kimko, Erkki Lathouwers, James Witek, Rodica Van Solingen-Ristea. Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. Annals of Hepatology (in press).

Rajoriya N, Leithead JA, Elsharkawy AM, Gunson BK, Perera TM, Mutimer D. The impact of the UKELD score on outcomes of patients listed for late hepatic artery thrombosis. Liver Transpl. 2015 Oct 19. doi: 10.1002/lt.24358. [Epub ahead of print]

Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Luisa Esposito M, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans. Hepatology. 2015 Oct 16. doi: 10.1002/hep.28294. [Epub ahead of print]

Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ. Effect of scavenger receptor BI antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.
Liver Transpl. 2015 Oct 5. doi: 10.1002/lt.24349. [Epub ahead of print]

Krishnamoorthy TL, Mutimer D. Hepatitis B: encouraging the use of interferon. Curr Opin Infect Dis. 2015 Dec;28(6):557-62.

Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4.

Li KK, Trivedi PJ, Von Heimendahl S, Bruns T, Ward ST, Oo Y, Mutimer D. Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how? Hepatology. 2015 Jun 4. doi: 10.1002/hep.27924. [Epub ahead of print].

Lim TR, Mutimer DJ. The association of hepatitis C virus infection and post-liver transplant diabetes. Aliment Pharmacol Ther. 2015 Mar;41(5):488.

Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015 Aug;64(8):1289-95.

Mutimer D. Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands. Gut. 2015 Feb;64(2):190-1.

Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014 May 22;370(21):1993-2001.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889-98.

Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, Fisher M, Geretti AM, James R, Kulasegaram R, Leen C, Mutimer D, Orkin C, Page E, Palfreeman A, Papineni P, Rodger A, Tong CY; British HIV Association. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013 Nov;14 Suppl 4:1-71.

Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R; REFINE Study Group. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. Am J Transplant. 2014 Mar;14(3):635-46.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection. European Association for Study of Liver. J Hepatol. 2014 Feb;60(2):392-420.

Lim TR, Tan BH, Mutimer DJ. Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection. Int J Antimicrob Agents. 2014 Jan;43(1):17-25.

Rowe IA, Parker R, Armstrong MJ, King AL, Houlihan DD, Mutimer DJ. Improving the quality of clinical practice guidelines for clinicians and patients. Hepatology. 2014 May;59(5):2055-6.